Hyponatremia and the use of vasopressin receptor antagonists in critically Ill patients

Journal of Intensive Care Medicine

Volumn 27, Issue 4, 2012, Pages 207-218

  Lehrich, Ruediger W ^a   Greenberg, Arthur ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

arginine vasopressin; conivaptan; critically ill patients; hyponatremia; SIADH; tolvaptan; vasopressin receptor antagonists

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; CONIVAPTAN; DEMECLOCYCLINE; HYPOTONIC SOLUTION; LIXIVAPTAN; LOOP DIURETIC AGENT; MOZAVAPTAN; PLACEBO; SODIUM CHLORIDE; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V3 RECEPTOR;

APPLICATION SITE INFECTION; ARTICLE; ASCITES; ASTHENIA; BRAIN EDEMA; CEREBRAL SALT WASTING; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DEMYELINATING DISEASE; DRUG DOSE TITRATION; FEVER; HEADACHE; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERVOLEMIA; HYPOKALEMIA; HYPONATREMIA; LIMB WEAKNESS; LIVER CIRRHOSIS; LOADING DRUG DOSE; LUNG CARCINOMA; MUSCLE FATIGUE; NAUSEA; ORTHOSTATIC HYPOTENSION; OSMOREGULATION; PERIPHERAL EDEMA; POLLAKISURIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINARY TRACT INFECTION; VASOPRESSIN RELEASE; WATER DEPRIVATION; XEROSTOMIA;

BENZAZEPINES; CRITICAL ILLNESS; HORMONE ANTAGONISTS; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN;

EID: 84863598231     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066610397016     Document Type: Article

References (79)

1. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006 ; 119 (7 suppl 1). S30 - S35
2. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000 ; 342 (20). 1581-1589 (Pubitemid 30340505)
3. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med. 1988 ; 319 (17). 1127-1134
4. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med. 1988 ; 319 (16). 1065-1072
5. DeVita MV, Gardenswartz MH, Konecky A, Zabetakis PM. Incidence and etiology of hyponatremia in an intensive care unit. Clin Nephrol. 1990 ; 34 (4). 163-166 (Pubitemid 20342876)
6. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1958 ; 102 (2). 164-168
7. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006 ; 69 (12). 2124-2130 (Pubitemid 43882098)
8. Lehrich RW, Greenberg A. When is it appropriate to use vasopressin receptor antagonists?. J Am Soc Nephrol. 2008 ; 19 (6). 1054-1058
9. Fraser CL, Arieff AI. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med. 1997 ; 102 (1). 67-77 (Pubitemid 27089989)
10. Sedlacek M, Schoolwerth AC, Remillard BD. Electrolyte disturbances in the intensive care unit. Semin Dial. 2006 ; 19 (6). 496-501 (Pubitemid 44736556)
11. Bennani SL, Abouqal R, Zeggwagh AA, et al. [Incidence, causes and prognostic factors of hyponatremia in intensive care]. Rev Med Interne. 2003 ; 24 (4). 224-229 (Pubitemid 36542165)
12. Friedman E, Shadel M, Halkin H, Farfel Z. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Intern Med. 1989 ; 110 (1). 24-30 (Pubitemid 19032790)
13. Sonnenblick M, Algur N, Rosin A. Thiazide-induced hyponatremia and vasopressin release.[comment]. Ann Int Med. 1989 ; 110 (9). 751
14. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. [Review] [66 refs]. Chest. 1993 ; 103 (2). 601-606 (Pubitemid 23070771)
15. Friedman E, Shadel M, Halkin H, Farfel Z. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis [see comment]. Ann Int Med. 1989 ; 110 (1). 24-30 (Pubitemid 19032790)
16. Harrigan MR. Cerebral salt wasting syndrome. Crit Care Clin. 2001 ; 17: 125-138 (Pubitemid 32163182)
17. Berendes E, Walter M, Cullen P, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet. 1997 ; 349: 245-249 (Pubitemid 27050991)
18. Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E. Is it cerebral or renal salt wasting?. Kidney Int. 2009 ; 76 (9). 934-938
19. Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference?. J Am Soc Nephrol. 2008 ; 19 (2). 194-196 (Pubitemid 351240639)
20. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957 ; 23 (4). 529-542
21. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967 ; 42: 790-806
22. Klein L, O'Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol. 2003 ; 91 (9A). 18F - 40F (Pubitemid 36555737)
23. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med. 1998 ; 339 (8). 533-541 (Pubitemid 28384887)
24. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009 ; 361 (13). 1279-1290
25. Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine. 1976 ; 55 (2). 121-129
26. Verbalis JG, Gullans SR. Hyponatremia causes large sustained reductions in brain content of multiple organic osmolytes in rats. Brain Res. 1991 ; 567 (2). 274-282
27. Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med. 1993 ; 44: 289-301 (Pubitemid 23117868)
28. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest. 1993 ; 103 (2). 601-606 (Pubitemid 23070771)
29. Lauriat SM, Berl T. The hyponatremic patient: practical focus on therapy. J Am Soc Nephrol. 1997 ; 8: 1599-1607 (Pubitemid 27496480)
30. Norenberg MD, Leslie KO, Robertson AS. Association between rise in serum sodium and central pontine myelinolysis. Ann Neurol. 1982 ; 11 (2). 128-135 (Pubitemid 12162977)
31. Wright DG, Laureno R, Victor M. Pontine and extrapontine myelinolysis. Brain. 1979 ; 102 (2). 361-385 (Pubitemid 9161009)
32. Burcar PJ, Norenberg MD, Yarnell PR. Hyponatremia and central pontine myelinolysis. Neurology. 1977 ; 27 (3). 223-226 (Pubitemid 8063827)
33. Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med. 1997 ; 126 (1). 57-62 (Pubitemid 27021219)
34. Verbalis JG, Martinez AJ. Neurological and neuropathological sequelae of correction of chronic hyponatremia. Kidney Int. 1991 ; 39 (6). 1274-1282
35. Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994 ; 4 (8). 1522-1530
36. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007 ; 120 (11 suppl 1). S1 - S21
37. Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology. 2006 ; 105 (3). 599-612 (Pubitemid 44310444)
38. Leng G, Brown CH, Russell JA. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol. 1999 ; 57 (6). 625-655 (Pubitemid 29148418)
39. Goldsmith SR. Baroreceptor-mediated suppression of osmotically stimulated vasopressin in normal humans. J Appl Physiol. 1988 ; 65 (3). 1226-1230
40. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab. 2000 ; 11: 406-410
41. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol. 1997 ; 272 (1 pt 2). F3-12
42. Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998 ; 449: 251-276 (Pubitemid 28566397)
43. Aguilera G. Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol. 1994 ; 15 (4). 321-350
44. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002 ; 29: 1-9
45. Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science.. 1991 ; 252 (5005). :572-574
46. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 ; 105 (4). 787-791
47. Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest. 1993 ; 92 (6). 2653-2659 (Pubitemid 24006529)
48. Shimizu K. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans. Kidney Int. 1995 ; 48 (1). 220-226
49. Saito T, Ishikawa S, Abe K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab. 1997 ; 82 (4). 1054-1057 (Pubitemid 27166641)
50. Burnier M, Fricker AF, Hayoz D, Nussberger J, Brunner HR. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol. 1999 ; 55 (9). 633-637
51. Macion-Dazard R, Callahan N, Xu Z, Wu N, Thibonnier M, Shoham M. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther. 2006 ; 316 (2). 564-571 (Pubitemid 43130982)
52. Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008 ; 3 (2). 331-336
53. Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007 ; 2 (6). 1110-1117
54. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med. 2001 ; 110 (7). 582-584
55. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006 ; 91 (6). 2145-2152 (Pubitemid 43854997)
56. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Am J Nephrol. 2007 ; 27 (5). 447-457
57. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006 ; 355 (20). 2099-2112 (Pubitemid 44749318)
58. Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003 ; 146 (1). 9-18 (Pubitemid 36851295)
59. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981 ; 305 (5). 263-266 (Pubitemid 11087371)
60. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994 ; 267 (6 pt 2). H2245-2254
61. Martin PY, Abraham WT, Lieming X, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol. 1999 ; 10 (10). 2165-2170 (Pubitemid 29453494)
62. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004 ; 291 (16). 1963-1971 (Pubitemid 38544277)
63. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003 ; 107 (21). 2690-2696 (Pubitemid 36667242)
64. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007 ; 297 (12). 1332-1343 (Pubitemid 46513234)
65. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 ; 297 (12). 1319-1331 (Pubitemid 46513233)
66. Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982 ; 96 (4). 413-417 (Pubitemid 12139861)
67. Niederberger M, Martin PY, Gines P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology. 1995 ; 109 (5). 1624-1630
68. Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest. 1998 ; 101 (1). 235-242 (Pubitemid 28058923)
69. Claria J, Jimenez W, Arroyo V, et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology. 1989 ; 97 (5). 1294-1299 (Pubitemid 19258716)
70. Asahina Y, Izumi N, Enomoto N, et al. Increased gene expression of water channel in cirrhotic rat kidneys. Hepatology. 1995 ; 21 (11). 169-173
71. Fujita N, Ishikawa SE, Sasaki S, et al. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats. Am J Physiol. 1995 ; 269 (6 pt 2). F926-931
72. Inoue T, Ohnishi A, Matsuo A, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther. 1998 ; 63 (5). 561-570 (Pubitemid 28277277)
73. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003 ; 124 (4). 933-939 (Pubitemid 36389796)
74. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003 ; 37 (1). 182-191 (Pubitemid 36042159)
75. Bhardwaj A. Neurological impact of vasopressin dysregulation and hyponatremia. Ann Neurol. 2006 ; 59 (2). 229-236 (Pubitemid 43202475)
76. Hasan D, Wijdicks EF, Vermeulen M. Hyponatremia is associated with cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. Ann Neurol. 1990 ; 27 (1). 106-108 (Pubitemid 20031367)
77. Karandanis D, Shulman JA. Recent survey of infectious meningitis in adults: review of laboratory findings in bacterial, tuberculous, and aseptic meningitis. South Med J. 1976 ; 69 (4). 449-457
78. Wijdicks EF, Vermeulen M, Hijdra A, van Gijn J. Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful?. Ann Neurol. 1985 ; 17 (2). 137-140 (Pubitemid 15170433)
79. Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care. 2009 ; 11 (1). 14-19